Skip to main content

Advertisement

Log in

Clinical analysis of macrophage activation syndrome in pediatric patients with autoimmune diseases

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Macrophage activation syndrome (MAS) belongs to secondary hemophagocytic lymphohistiocytosis (HLH) syndrome. It is usually associated with rheumatic diseases. We retrospectively reviewed our hospital’s medical records of 102 HLH/MAS patients from the past 20 years. Demographics, clinical data, treatment, and outcomes were analyzed. Among 102 patients, eight patients with underlying juvenile systemic lupus erythematous (two patients), mixed connective tissue disease (one patient), primary anti-phospholipid syndrome (one patient), and systemic type juvenile rheumatoid arthritis (sJRA; four patients) with 13 episodes of MAS were studied. Clinical manifestations of MAS included fever (100 %), hepatosplenomegaly (77 %), lymphadenopathy (38 %), skin rash (62 %), and neurological involvement (31 %). Laboratory features included leukopenia (54 %), anemia (46 %), thrombocytopenia (77 %), jaundice (27 %), hypofibrinogenemia (40 %), decreased erythrocyte sedimentation rate (67 %), and elevated liver enzymes (77 %), lactate dehydrogenase (100 %), ferritin (88 %), triglycerides (91 %), C-reactive protein (85 %), plasma D-dimer (50 %), and hemophagocytosis in bone marrow (83 %). The Epstein–Barr virus and adenovirus infection triggered MAS in two patients with sJRA. Methylprednisolone pulse therapy was effective in two out of three patients, and high-dose intravenous immunoglobulin (IVIG) was effective in two out of six patients. Patients with sJRA responded well to corticosteroids and cyclosporine. Complications included opportunistic infection with Pneumocystis jiroveci, multiple organ failure, and intensive care unit myopathy. The mortality rate was one out of eight (12.5 %). Our results showed that MAS could be fatal and complicate various pediatric autoimmune diseases. It generally has a good response to corticosteroids and IVIG. Prompt recognition and timely treatment can result in good outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ramanan AV, Schneider R (2003) Macrophage activation syndrome—what’s in a name! J Rheumatol 30(12):2513–2516

    PubMed  Google Scholar 

  2. Hadchouel M, Prieur AM, Griscelli C (1985) Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: Possible relationship to drugs or infection. J Pediatr 106(4):561–566

    Article  PubMed  CAS  Google Scholar 

  3. Kumakura S, Ishikura H, Kondo M, Murakawa Y, Masuda J, Kobayashi S (2004) Autoimmune-associated hemophagocytic syndrome. Mod Rheumatol 14(3):205–215

    Article  PubMed  Google Scholar 

  4. Deane S, Selmi C, Teuber SS, Gershwin ME (2010) Macrophage activation syndrome in autoimmune disease. Int Arch Allergy Immunol 153(2):109–120

    Article  PubMed  CAS  Google Scholar 

  5. Lin YT, Wang CT, Gershwin ME, Chiang BL (2011) The pathogenesis of oligoarticular/polyarticular vs systemic juvenile idiopathic arthritis. Autoimmun Rev 10(8):482–489

    Article  PubMed  CAS  Google Scholar 

  6. Villanueva J, Lee S, Giannini EH, Graham TB, Passo MH, Filipovich A, Grom AA (2005) Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther 7(1):R30–R37

    Article  PubMed  CAS  Google Scholar 

  7. Stepp SE, Dufourcq-Lagelouse R, Le Deist F, Bhawan S, Certain S, Mathew PA, Henter JI, Bennett M, Fischer A, de Saint BG, Kumar V (1999) Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 286(5446):1957–1959

    Article  PubMed  CAS  Google Scholar 

  8. Hazen MM, Woodward AL, Hofmann I, Degar BA, Grom AA, Filipovich AH, Binstadt BA (2008) Mutations of the hemophagocytic lymphohistiocytosis-associated gene UNC13D in a patient with systemic juvenile idiopathic arthritis. Arthritis Rheum 58(2):567–570

    Article  PubMed  CAS  Google Scholar 

  9. Zhang K, Biroschak J, Glass DN, Thompson SD, Finkel T, Passo MH, Binstadt BA, Filipovich A, Grom AA (2008) Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. Arthritis Rheum 58(9):2892–2896

    Article  PubMed  Google Scholar 

  10. Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain J, Webb D, Winiarski J, Janka G (2007) HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48(2):124–131

    Article  PubMed  Google Scholar 

  11. Ravelli A, Magni-Manzoni S, Pistorio A, Besana C, Foti T, Ruperto N, Viola S, Martini A (2005) Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr 146(5):568–604

    Google Scholar 

  12. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725–1734

    Article  PubMed  CAS  Google Scholar 

  13. Gladman DD, Ibañez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29(2):288–291

    PubMed  Google Scholar 

  14. Brewer EJ, Bass J, Baum J, Cassidy JT, Fink C, Jacobs J, Hanson V, Levinson JE, Schaller J, Stillman JS (1977) Current proposed revision of JRA Criteria. JRA Criteria Subcommittee of the Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Section of The Arthritis Foundation. Arthritis Rheum 20(suppl):195–199

    PubMed  Google Scholar 

  15. Yao TC, Kuo ML, See LC, Ou LS, Lee WI, Chan CK, Huang JL (2006) RANTES and monocyte chemoattractant protein 1 as sensitive markers of disease activity in patients with juvenile rheumatoid arthritis: a six-year longitudinal study. Arthritis Rheum 54(8):2585–2593

    Article  PubMed  CAS  Google Scholar 

  16. Kasukawa R, Sharp GC (1987) Preliminary diagnostic criteria for classification of mixed connective tissue disease. In: Kasukawa R, Sharp GC (eds) Mixed connective tissue disease and antinuclear antibodies. Elsevier, Amsterdam, pp 41–48

    Google Scholar 

  17. Lage LV, Caleiro MT, Carvalho JF (2010) Proposed disease activity criteria for mixed connective tissue disease. Lupus 19(2):223–224

    Article  PubMed  CAS  Google Scholar 

  18. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RHWM, De Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4(2):295–306

    Article  PubMed  CAS  Google Scholar 

  19. Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M (2001) Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 86(5):1327–1330

    PubMed  CAS  Google Scholar 

  20. McCann LJ, Hasson N, Pilkington CA (2006) Macrophage activation syndrome as an early presentation of Lupus. J Rheumatol 33(2):438–440

    PubMed  Google Scholar 

  21. Kaneko K, Takahashi K, Fujiwara S, Maruyama T, Obinata K (1998) Kawasaki disease followed by haemophagocytic syndrome. Eur J Pediatr 157(7):610–611

    Article  PubMed  CAS  Google Scholar 

  22. Kobayashi I, Yamada M, Kawamura N, Kobayashi R, Okano M, Kobayashi K (2000) Platelet-specific hemophagocytosis in a patient with juvenile dermatomyositis. Acta Paediatr 89(5):617–619

    Article  PubMed  CAS  Google Scholar 

  23. Kato M, Sato S, Suzuki M, Oka H, Kaneko Y, Yasuoka H, Nojima T, Suwa A, Hirakata M, Ikeda Y (2004) A case of mixed connective tissue disease successfully treated for hemophagocytic syndrome with intermittent intravenous injection of cyclophosphamide. Jpn J Clin Immunol 27(5):345–349

    Article  Google Scholar 

  24. Maruyama J, Inokuma S (2010) Cytokine profiles of macrophage activation syndrome associated with rheumatic diseases. J Rheumatol 37(5):967–973

    Article  PubMed  CAS  Google Scholar 

  25. Stéphan JL, Koné-Paut I, Galambrun C, Mouy R, Bader-Meunier B, Prieur AM (2001) Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. Rheumatology (Oxford) 40(11):1285–1292

    Article  Google Scholar 

  26. Yu HH, Lee JH, Wang LC, Lin YT, Yang YH, Chiang BL (2006) Neuropsychiatric manifestations in pediatric systemic lupus erythematosus: a 20-year study. Lupus 15(10):651–657

    Article  PubMed  CAS  Google Scholar 

  27. Behrens EM, Beukelman T, Paessler M, Cron RQ (2007) Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 34(5):1133–1138

    PubMed  Google Scholar 

  28. Grom AA (2010) Macrophage activation syndrome. In: Cassidy JT, Petty RE, Laxer R, Lindsay C (eds) Textbook of pediatric rheumatology, vol 45, 6th edn. Saunders, Philadelphia, pp 674–681

    Google Scholar 

  29. Bleesing J, Prada A, Siegel DM, Villanueva J, Olson J, Ilowite NT, Brunner HI, Griffin T, Graham TB, Sherry DD, Passo MH, Ramanan AV, Filipovich A, Grom AA (2007) The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor α-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum 56(3):965–971

    Article  PubMed  CAS  Google Scholar 

  30. Shigemura T, Yamazaki T, Hara Y, Ou JN, Stevens AM, Ochs HD, Koike K, Agematsu K (2011) Monitoring serum IL-18 levels is useful for treatment of a patient with systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome. Pediatr Rheumatol Online J 9(1):15

    Article  PubMed  Google Scholar 

  31. Fukaya S, Yasuda S, Hashimoto T, Oku K, Kataoka H, Horita T, Atsumi T, Koike T (2008) Clinical features of haemophagocytic syndrome in patients with systemic autoimmune diseases: analysis of 30 cases. Rheumatology (Oxford) 47(11):1686–1691

    Article  CAS  Google Scholar 

  32. Parodi A, Davì S, Pringe AB, Pistorio A, Ruperto N, Magni-Manzoni S, Miettunen P, Bader-Meunier B, Espada G, Sterba G, Ozen S, Wright D, Magalhães CS, Khubchandani R, Michels H, Woo P, Iglesias A, Guseinova D, Bracaglia C, Hayward K, Wouters C, Grom A, Vivarelli M, Fischer A, Breda L, Martini A, Ravelli A (2009) Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients. Arthritis Rheum 60(11):3388–3399

    Article  PubMed  CAS  Google Scholar 

  33. Chen HH, Kuo HC, Wang L, Yu HR, Shen JM, Hwang KP, Yang KD (2007) Childhood macrophage activation syndrome differs from infection-associated hemophagocytosis syndrome in etiology and outcome in Taiwan. J Microbiol Immunol Infect 40(3):265–271

    PubMed  CAS  Google Scholar 

  34. Singh S, Chandrakasan S, Ahluwalia J, Suri D, Rawat A, Ahmed N, Das R, Sachdeva M, Varma N (2011) Macrophage activation syndrome in children with systemic onset juvenile idiopathic arthritis: clinical experience from northwest India. Rheumatol Int (epub). doi:10.1007/s00296-010-1711-z

  35. Hot A, Madoux MH, Viard JP, Coppéré B, Ninet J (2008) Successful treatment of cytomegalovirus-associated hemophagocytic syndrome by intravenous immunoglobulins. Am J Hematol 83(2):159–162

    Article  PubMed  CAS  Google Scholar 

  36. Katz U, Achiron A, Sherer Y, Shoenfeld Y (2007) Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev 6(4):257–259

    Article  PubMed  CAS  Google Scholar 

  37. Ravelli A, De Benedetti F, Viola S, Martini A (1996) Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. J Pediatr 128(2):275–278

    Article  PubMed  CAS  Google Scholar 

  38. Ramanan AV, Schneider R (2003) Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J Rheumatol 30(2):401–403

    PubMed  Google Scholar 

  39. Bruck N, Suttorp M, Kabus M, Heubner G, Gahr M, Pessler F (2011) Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids. J Clin Rheumatol 17(1):23–27

    PubMed  Google Scholar 

  40. Sawhney S, Woo P, Murray KJ (2001) Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child 85(5):421–426

    Article  PubMed  CAS  Google Scholar 

  41. Pinto L, Kagalwala F, Singh S, Balakrishnan C, Prabhu SV, Khodaiji S (2007) Macrophage activation syndrome: experience from a tertiary referral centre. J Assoc Physicians India 55:185–187

    PubMed  CAS  Google Scholar 

  42. Kaito K, Kobayashi M, Katayama T, Otsubo H, Ogasawara Y, Sekita T, Saeki A, Sakamoto M, Nishiwaki K, Masuoka H, Shimada T, Yoshida M, Hosoya T (1997) Prognostic factors of hemophagocytic syndrome in adults: analysis of 34 cases. Eur J Haematol 59(4):247–253

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosures

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Bor-Luen Chiang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lin, CI., Yu, HH., Lee, JH. et al. Clinical analysis of macrophage activation syndrome in pediatric patients with autoimmune diseases. Clin Rheumatol 31, 1223–1230 (2012). https://doi.org/10.1007/s10067-012-1998-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-012-1998-0

Keywords

Navigation